Adaptive resistance to FLT3 inhibitors is potentiated by ROS-driven DNA repair signalling

Dilana E Staudt,Zacary P Germon,Abdul Mannan,Tabitha McLachlan,Heather C Murray,Ryan J Duchatel,Bryce C Thomas,Tyrone Beitaki,Holly P McEwen,Mika L Persson,Leah Calvert,Izac J Findlay,Evangeline R Jackson,Nathan D Smith,David A Skerrett-Byrne,David Mossman,Brett Nixon,Geoffry De Iullis,Alicia M Douglas,Anoop K Enjeti,Jonathan R Sillar,Janis Chamberlain,Frank Alvaro,Andrew H Wei,Patrick Connerty,Nicole Verrills,Matthew D Dun

DOI: https://doi.org/10.1101/2024.07.26.605229

2024-07-26

Abstract:Alterations in the FMS-like tyrosine kinase 3 (FLT3) gene are the most frequent driver mutations in acute myeloid leukaemia (AML), linked to a high risk of relapse in patients with internal tandem duplications (FLT3-ITD). Tyrosine kinase inhibitors (TKIs) targeting the FLT3 protein are approved for clinical use, yet resistance often emerges. This resistance is mainly seen following the acquisition of additional point mutations in the tyrosine kinase domain (TKD), resulting in a double mutant FLT3-ITD/TKD, which sustains cell signalling and survival despite the presence of FLT3 inhibitors. Here, we developed a FLT3-mutant AML model with adaptive resistance to type II TKIs, sorafenib, and quizartinib by in vitro drug selection. Through global multiomic profiling, we identified upregulation of proteins involved in reactive oxygen species (ROS) production, particularly NADPH-oxidases, driving cellular 'ROS-addiction', with resistant cells relying on ROS for survival, and genome fidelity preserved by ATM-driven DNA repair. Transcriptomic analysis of adult and paediatric AML (pAML) patients identified high ATM expression as a biomarker for shorter median overall survival in both the de novo and relapsed settings. Inhibition of ATM with clinically relevant therapy WSD-0628 effectively killed TKI- and chemotherapy-resistant AML cells in vitro and significantly extended the survival of mice with sorafenib- and quizartinib-resistant FLT3-ITD AML in vivo. We propose a new treatment strategy to improve survival of patients who develop resistance to sorafenib and quizartinib, as well as relapsed and refractory pAML, exploiting resistance mechanisms to precision therapies and cell-intrinsic features of high-risk cases, highlighting a clinically relevant salvage strategy.

Cancer Biology

What problem does this paper attempt to address?

This paper aims to address the problem of adaptive resistance to FLT3 inhibitors in acute myeloid leukemia (AML). Specifically, the study focused on the high recurrence risk and poor survival rate of AML patients caused by FLT3 gene mutations (especially the internal tandem duplication mutation FLT3 - ITD). Although tyrosine kinase inhibitors (TKIs) targeting the FLT3 protein have been developed, resistance remains a major challenge, mainly due to the acquisition of additional point mutations in the tyrosine kinase domain (TKD), resulting in the emergence of the double - mutant FLT3 - ITD/TKD. This mutant can maintain cell signaling and survival even in the presence of FLT3 inhibitors.

To meet this challenge, researchers developed an FLT3 - mutant AML model with adaptive resistance through in vitro drug selection. Through global multi - omics analysis, they found that proteins related to reactive oxygen species (ROS) generation were up - regulated in resistant cells, especially the increased expression of NADPH oxidase, leading to "ROS addiction" of the cells and their dependence on ROS for survival. Meanwhile, the ATM - driven DNA repair mechanism maintained genomic stability, enabling these cells to survive at high ROS levels.

Further research has shown that an elevated ATM expression level is a poor prognostic marker in adult and pediatric AML patients, both at initial diagnosis and at relapse. Inhibition of ATM using the clinically relevant therapy WSD - 0628 can effectively kill AML cells resistant to TKI and chemotherapy and significantly prolong the survival of mice carrying resistant FLT3 - ITD AML. Therefore, this study proposes a new treatment strategy to improve the survival rate of sorafenib - and quizartinib - resistant and relapsed or refractory pediatric AML patients by targeting ATM, taking advantage of the resistance mechanism and the cell - intrinsic characteristics of high - risk cases, and proposing a clinically significant salvage strategy.